Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GBA1 | P04062 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.51 |
| ▸ | HRH2 | P25021 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Neltenexine SCHEMBL10646479 | 1.00 | CYP1A2 (0.51) | CYP1A2CYP2D6LMNAGBA1CNR1 | |
| Neltenexine SCHEMBL30712623 | 1.00 | CYP1A2 (0.51) | CYP1A2CYP2D6LMNAGBA1CNR1 | |
| Neltenexine SCHEMBL15673426 | 0.99 | CYP3A4 (0.52) | CYP1A2CYP2D6LMNAGBA1CNR1 | |
| Neltenexine SCHEMBL10650927 | 0.99 | CYP3A4 (0.52) | CYP1A2CYP2D6LMNAGBA1CNR1 | |
| Neltenexine SCHEMBL13723560 | 0.87 | LMNA (0.39) | CYP1A2CYP2D6LMNAGBA1CNR1 | |
| SCHEMBL9292739 | 0.83 | LMNA (0.55) | CYP1A2CYP2D6LMNAGBA1CNR1 | |
| Hydrochloric Acid SCHEMBL9293916 | 0.82 | CYP3A4 (0.56) | CYP1A2CYP2D6LMNAGBA1CNR1 | |
| SCHEMBL16709538 | 0.77 | LMNA (0.53) | CYP1A2CYP2D6LMNAGBA1CNR1 | |
| SCHEMBL10646050 | 0.76 | GRIN2D (0.41) | CYP1A2CYP2D6LMNACYP3A4TSHR | |
| SCHEMBL28774653 | 0.75 | LMNA (0.56) | CYP1A2CYP2D6LMNAGBA1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1612 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| US-12296043-B2 | Liquisoft capsules | PATHEON SOFTGELS INC. (US) | 2025-05-13 | — | — | US | claimed |
| EP-4510999-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | Bristol-Myers Squibb Company (US) | 2025-02-26 | — | — | EP | claimed |
| US-20240165020-A1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-05-23 | — | — | US | claimed |
| EP-4360653-A2 | LIQUISOFT CAPSULES | Patheon Softgels Inc. (US) | 2024-05-01 | — | — | EP | claimed |
| US-11872307-B2 | Liquisoft capsules | PATHEON SOFTGELS INC. (US) | 2024-01-16 | — | — | US | claimed |
| EP-3682872-B1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-01-03 | — | — | EP | claimed |
| WO-2023205619-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-26 | — | — | WO | claimed |
| US-20230118307-A1 | THERAPEUTIC USE OF LONG-ACTING CONJUGATE OF TRIPLE AGONIST HAVING ACTIVITIES TO ALL OF GLUCAGON/GLP-1/GIP RECEPTORS FOR LUNG DISEASE | HANMI PHARM. CO., LTD. (KR) | 2023-04-20 | — | — | US | claimed |
| EP-4104849-A1 | THERAPEUTIC USE OF LONG-ACTING CONJUGATE OF TRIPLE AGONIST HAVING ACTIVITY WITH RESPECT TO ALL OF GLUCAGON AND GLP-1 AND GIP RECEPTORS AGAINST LUNG DISEASE | Hanmi Pharm. Co., Ltd. (KR) | 2022-12-21 | — | — | EP | claimed |
| WO-2012069175-A1 | NEW PYRAZOLE DERIVATIVES HAVING CRTH2 ANTAGONISTIC BEHAVIOUR | ALMIRALL, S.A. (ES) | 2012-05-31 | — | — | WO | claimed |
| EP-2457900-A1 | New pyrazole derivatives having CRTh2 antagonistic behaviour | Almirall, S.A. (ES) | 2012-05-30 | — | — | EP | claimed |
| WO-2012025761-A1 | THEOBROMINE IN COMBINATION WITH AN EXPECTORANT OR A MUCOLYTIC FOR USE IN THERAPY | BIOCOPEA LIMITED (GB) | 2012-03-01 | — | — | WO | claimed |
| CN-101835749-A | The indoles that replaces | AUSPEX PHARAMACEUTICALS INC | 2010-09-15 | — | — | CN | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230118307-A1 | THERAPEUTIC USE OF LONG-ACTING CONJUGATE OF TRIPLE AGONIST HAVING ACTIVITIES TO ALL OF GLUCAGON/GLP-1/GIP RECEPTORS FOR LUNG DISEASE | GIPR, GLP1R, GCGR | CYP1A2 4838/4885CYP2D6 4765/4885LMNA 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.